CAR-T

Hope For Patients of Gastric Cancer And Pancreatic Cancer – CT041 Typical Cases and Achievements

🔬✨Hope For Patients of Gastric And Pancreatic Cancer – CT041 Typical Cases and Achievements ✨🔬   Patient 1: 53-year-old Male Advanced gastric cancer with liver, lung, bone metastases, and multiple lymph nodes and peritoneal metastases. Previously treated with 2 systemic therapies including PD-1 antibodies, CLDN18.2 expression 60% (3+). After CAR-T therapy, tumor size decreased by Read More

February 14th,2024 CAR-T

Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results!

🎉 Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results! 🚀 A burgeoning therapeutic target for gastric cancer—Claudin 18.2, its discovery has also opened a new chapter in targeted therapy for gastric cancer. If we talk about the hottest cell Read More

February 13th,2024 CAR-T

Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!

🌟✨ **Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!** ✨🌟 🔬 On January 2, 2024, a groundbreaking clinical study from China was published in *Nature*. This study, employing engineering design, enables CAR-T cells to secrete Interleukin-10 (IL-10), thereby enhancing metabolism within the tumor microenvironment. The modified IL-10 CAR-T cells increase oxidative phosphorylation in Read More

February 8th,2024 CAR-T

Haematologica Spotlight：A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

🔬 *Haematologica Spotlight* 🔬 A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL Acute Lymphoblastic Leukemia (ALL)     is a hematological malignancy characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and extramedullary sites. While the prognosis for childhood ALL is relatively favorable, with a Read More

February 7th,2024 CAR-T

Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients

🌟 Miracle Unfolds: Zhejiang University Hospital’s Custom CRISPR/Cas9 Gene Editing + CAR-T Cell Therapy Rebirths Patients 🌟   👨‍👧‍👦 (“I want to live to see my child go to university!”)👨‍👧‍👦   🎓 This heartfelt cry came from Mr. Sun, a 40-year-old patient from Guangzhou, who faced the formidable challenge of diffuse large B-cell lymphoma, a Read More

February 6th,2024 CAR-T

Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology

🔬 Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology 🔬   The clinical research achievements conducted by Professor Huang He’s team from the First Affiliated Hospital of Zhejiang University School of Medicine have been published online in the top international journal Nature under the title “Non-viral, specifically targeted CAR-T cells achieve high Read More

February 5th,2024 CAR-T

Introducing China’s Top 10 Leading Cancer Hospitals!

🏥✨ Introducing China’s Top 10 Leading Cancer Hospitals! 🏥✨ 1. Cancer Hospital, Chinese Academy of Medical Sciences 🍏🍏 http://www.cicams.ac.cn/ Located in Beijing, a Grade A tertiary hospital, China’s first specialized cancer hospital. It serves as the National Clinical Medical Research Center for Malignant Tumors, the National Standardized Diagnosis and Treatment Center for Tumors, the National Read More

February 2nd,2024 CAR-T

World’s First! Chinese Tongji Hospital Successfully Treats Immune-Mediated Necrotizing Myopathy with CAR-T Cells!

🎉🔬✨ World’s First! Chinese Tongji Hospital Successfully Treats Immune-Mediated Necrotizing Myopathy with CAR-T Cells! ✨🔬🎉 🌟A groundbreaking achievement in medicine! Immune-Mediated Necrotizing Myopathy Professor Wang Wei’s team from Tongji Hospital, affiliated with Huazhong University of Science and Technology, has brought unprecedented hope to patients with immune-mediated necrotizing myopathy. 🌟 📅 On January 30th, their research Read More

February 1st,2024 CAR-T

Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma!

🌟 Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma! 🌟 “Engineered T Cell Receptor-T Cell Therapy,” or “TCR-T (engineered T cell receptor-T cell, TCR-T) cell therapy,” involves the extraction of peripheral blood mononuclear cell (PBMC) samples from patients, followed by genetic engineering to introduce selected high-affinity T cell receptors (TCRs) into Read More

January 30th,2024 CAR-T

A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options!

**🌟 A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options! 🌟**   📆CANCER CELL         January 5, 2023: The highly anticipated Phase 3 pivotal clinical trial (ASTRUM-004) of HANSIZHUANG, an anti-PD-1 monoclonal antibody developed independently by Henlius, in combination with chemotherapy for first-line treatment of advanced Read More

January 29th,2024 CAR-T

Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.

🌟 Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.🌟 🏥💊（Jiangsu Hengrui Pharmaceuticals Co., Ltd）Hengrui Pharmaceutical’s PD-L1 inhibitor Atezolizumab injection combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer has been approved for open, multicenter Phase II clinical trials. 🌸🎀#Cervical cancer is the fourth most common cancer Read More

January 26th,2024 CAR-T

Chinese Exciting Good News Update in Lung Cancer Treatment! ORR: 78.6%

Chinese Exciting Good News Update in Lung Cancer Treatment! ORR: 78.6% Meet Sunvozertinib, the game-changer in advanced lung cancer therapy! This groundbreaking oral medication, a novel irreversible EGFR-TKI, targets multiple EGFR mutation subtypes with remarkable precision. What’s more? Sunvozertinib is now the FIRST and ONLY EGFR-TKI approved for treating late-stage NSCLC with EGFR exon20ins mutations! Read More

January 25th,2024 CAR-T